Previous 10 | Next 10 |
home / stock / nonof / nonof news
2023-10-18 08:30:00 ET Summary Mawer Investment Management is a privately owned, independent investment firm, managing over $67B in assets for individual and institutional investors across all major asset classes. This quarter there was a divergence in the performance of holdings ...
2023-10-17 12:08:30 ET More on Johnson & Johnson Johnson & Johnson: A Conservative High-Yield Dividend Aristocrat Buy Johnson & Johnson Q3 Earnings Preview: Don't Count On Different Proposition Post Kenvue Spin-Out Johnson & Johnson: The Bull Case Can...
2023-10-16 02:53:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. The tech-focused rally...
2023-10-13 07:25:00 ET Summary Consumer staples stocks, including legendary dividend stocks like Hormel Foods Corporation and Kellanova (formerly Kellogg), have crashed between 20% to 30%. The media has attributed the decline in consumer staples to factors such as weight loss drug...
2023-10-06 23:40:19 ET More on Novo Nordisk Novo Nordisk: DCF Analysis Suggests Significant Undervaluation Novo Nordisk: Catching The Falling Knife Now Could Really Hurt Novo Nordisk: What The Stock Split Means For Traders And Investors Walmart says Ozempic, ...
2023-10-06 18:09:48 ET Summary The biotechnology and pharmaceutical sectors have been under pressure in 2023, with the Invesco Pharmaceuticals ETF down 9% and the iShares Biotechnology ETF down 6%. Elevated interest rates and potential pricing power erosion are the primary headwin...
2023-10-06 13:09:10 ET More on Eli Lilly Eli Lilly: Big Cancer Bet With Point Biopharma Global Purchase Eli Lilly POINTs Toward Radiopharmaceutical Ambitions Eli Lilly: Don't Be Fooled By Greed Walmart says Ozempic, weight loss drugs impacting sales - Bloombe...
2023-10-02 14:55:14 ET More on Bristol-Myers, Merck, etc. Bristol-Myers: Out Of Favor (Rating Upgrade) Bristol-Myers Squibb: How Cheap Is Cheap Enough? Bristol-Myers Squibb Looks Grossly Overvalued With LOE Taking A Bite Out Of Topline Merck, Bristol Myers, A...
2023-10-02 12:59:17 ET More on Novo Novo Nordisk: DCF Analysis Suggests Significant Undervaluation Novo Nordisk: Catching The Falling Knife Now Could Really Hurt Novo Nordisk: What The Stock Split Means For Traders And Investors Novo Nordisk underperforms as ...
2023-10-01 12:00:03 ET More on Novo Nordisk Viatris: Generic Semaglutide Could Become The Poor Man's Option For Weight Loss Novo Nordisk: DCF Analysis Suggests Significant Undervaluation Novo Nordisk: Catching The Falling Knife Now Could Really Hurt Viatris a...
News, Short Squeeze, Breakout and More Instantly...
Partnership will leverage Aspect’s proprietary bioprinting technology and Novo Nordisk’s expertise and technology in stem cell differentiation and cell therapy development and manufacturing . Aspect to receive 75 million US dollars in initial payments and u...
New York City, NY: May 06, 2020 – Published via (Wired Release):- “Market.us presents a new report titled Alkyl Benzyl Dimethyl Ammonium Chloride Market: 2020 Research and New Innovations in Oil and Gas Sector. The prime objective of the report is to offer updates and information...